Primary gastric chorioadenocarcinoma: a needle in a haystack

por Shastri, Aditi, Daver, Naval G., Hayes, Teresa G.
Publicado 2011

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia

por Medeiros, Bruno C., Chan, Steven M., Daver, Naval G., Jonas, Brian A., Pollyea, Daniel A.
Publicado 2019

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

por Daver, Naval G., Iqbal, Shahed, Renard, Camille, Chan, Rebecca J., Hasegawa, Ken, Hu, Hao, Tse, Preston, Yan, Jiajun, Zoratti, Michael J., Xie, Feng, Ramsingh, Giridharan
Publicado 2023

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

por Daver, Naval G., Maiti, Abhishek, Kadia, Tapan M., Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H., Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A., Kantarjian, Hagop M.
Publicado 2022

Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience

por Nelson, Blessie Elizabeth, Ejezie, Chinenye Lynette, Stephen, Bettzy A., Nardo, Mirella, Campbell, Erick, Gong, Jing, Hong, David S., Fu, Siqing, Yap, Timothy A., Murphy, Mariela Blum, Piha-Paul, Sarina, Daver, Naval G., Rojas-Hernandez, Cristhiam M., Naing, Aung
Publicado 2022

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

por Nishida, Yuki, Ishizawa, Jo, Ayoub, Edward, Montoya, Rafael Heinz, Ostermann, Lauren B., Muftuoglu, Muharrem, Ruvolo, Vivian R, Patsilevas, Tallie, Scruggs, Darah A., Khazaei, Shayaun, Mak, Po Yee, Tao, Wenjing, Carter, Bing Z., Boettcher, Steffen, Ebert, Benjamin L., Daver, Naval G., Konopleva, Marina, Seki, Takahiko, Kojima, Kensuke, Andreeff, Michael
Publicado 2023

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

por Richard-Carpentier, Guillaume, Rausch, Caitlin R., Sasaki, Koji, Hammond, Danielle, Morita, Kiyomi, Takahashi, Koichi, Tang, Guilin, Kanagal-Shamanna, Rashmi, Bhalla, Kapil, Dinardo, Courtney D., Borthakur, Gautam, Pemmaraju, Naveen, Shpall, Elizabeth J., Alousi, Amin, Daver, Naval G., Garcia-Manero, Guillermo, Konopleva, Marina Y., Ravandi, Farhad, Kantarjian, Hagop M., Kadia, Tapan M.
Publicado 2023

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

por Richard-Carpentier, Guillaume, Kantarjian, Hagop M., Tang, Guilin, Yin, C. Cameron, Khoury, Joseph D., Issa, Ghayas C., Haddad, Fadi, Jain, Nitin, Ravandi, Farhad, Short, Nicholas J., DiNardo, Courtney D., Takahashi, Koichi, Konopleva, Marina Y., Daver, Naval G., Kadia, Tapan, Garcia-Manero, Guillermo, Garris, Rebecca, O’Brien, Susan, Jabbour, Elias
Publicado 2021

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

por Daver, Naval G., Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr M., Larson, Richard A., Asch, Adam S., Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany N., Bradley, Terrence J., Jeyakumar, Deepa, Wang, Eunice S., Sweet, Kendra, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua F., Sallman, David A.
Publicado 2023

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

por Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.
Publicado 2017

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

por Hammond, Danielle, Loghavi, Sanam, Wang, Sa A., Konopleva, Marina Y., Kadia, Tapan M., Daver, Naval G., Ohanian, Maro, Issa, Ghayas C., Alvarado, Yesid, Short, Nicholas J., Sasaki, Koji, Pemmaraju, Naveen, Montalban-Bravo, Guillermo, Lachowiez, Curtis A., Maiti, Abhishek, Garcia-Manero, Guillermo, Jabbour, Elias J., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Pierce, Sherry R., Kantarjian, Hagop M., DiNardo, Courtney D.
Publicado 2023

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

por Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina, Ning, Jing, Xiao, Lianchun, Hidalgo Lopez, Juliana, Kornblau, Steve M., Andreeff, Michael, Flores, Wilmer, Bueso‐Ramos, Carlos, Blando, Jorge, Galera, Pallavi, Calvo, Katherine R., Al‐Atrash, Gheath, Allison, James P., Kantarjian, Hagop M., Sharma, Padmanee, Daver, Naval G.
Publicado 2018

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

por Maiti, Abhishek, DiNardo, Courtney D., Daver, Naval G., Rausch, Caitlin R., Ravandi, Farhad, Kadia, Tapan M., Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Short, Nicholas J., Yilmaz, Musa, Montalban-Bravo, Guillermo, Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Ohanian, Maro, Takahashi, Koichi, Thompson, Philip A., Loghavi, Sanam, Montalbano, Kathryn S., Pierce, Sherry, Wierda, William G., Kantarjian, Hagop M., Konopleva, Marina Y.
Publicado 2021

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

por Daver, Naval G., Dail, Monique, Garcia, Jacqueline S., Jonas, Brian A., Yee, Karen W. L., Kelly, Kevin R., Vey, Norbert, Assouline, Sarit, Roboz, Gail J., Paolini, Stefania, Pollyea, Daniel A., Tafuri, Agostino, Brandwein, Joseph M., Pigneux, Arnaud, Powell, Bayard L., Fenaux, Pierre, Olin, Rebecca L., Visani, Giuseppe, Martinelli, Giovanni, Onishi, Maika, Wang, Jue, Huang, Weize, Green, Cherie, Ott, Marion G., Hong, Wan-Jen, Konopleva, Marina Y., Andreeff, Michael
Publicado 2023

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

por Yilmaz, Musa, Alfayez, Mansour, DiNardo, Courtney D., Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Jabbour, Elias J., Garcia-Manero, Guillermo, Pemmaraju, Naveen, Pierce, Sherry A., Ghayas, Issa, Short, Nicholas J., Montalban-Bravo, Guillermo, Takahashi, Koichi, Assi, Rita, Alotaibi, Ahmad S., Ohanian, Maro, Andreeff, Michael, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad, Daver, Naval G.
Publicado 2020

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

por Yilmaz, Musa, Alfayez, Mansour, DiNardo, Courtney D., Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Jabbour, Elias J., Garcia‑Manero, Guillermo, Pemmaraju, Naveen, Pierce, Sherry A., Ghayas, Issa, Short, Nicholas J., Montalban-Bravo, Guillermo, Takahashi, Koichi, Assi, Rita, Alotaibi, Ahmad S., Ohanian, Maro, Andreeff, Michael, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad, Daver, Naval G.
Publicado 2021

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience

por Altan, Mehmet, Soto, Felipe, Zhong, Linda L, Akhmedzhanov, Fechukwu O, Wilson, Nathaniel R, Zarifa, Abdulrazzak, Albittar, Aya A, Yang, Vincent, Lewis, Jeff, Rinsurongkawong, Waree, Jack Lee, J, Rinsurongkawong, Vadeerat, Zhang, Jianjun, Gibbons, Don L, Vaporciyan, Ara A, Jennings, Kristofer, Khawaja, Fareed, Faiz, Saadia A, Shannon, Vickie R, Shroff, Girish, Godoy, Myrna C B, Daver, Naval G, Gandhi, Saumil, Mendoza, Tito R, Naing, Aung, Daniel-MacDougall, Carrie, Heymach, John V, Sheshadri, Ajay
Publicado 2023

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens

por Maiti, Abhishek, Rausch, Caitlin R., Cortes, Jorge E., Pemmaraju, Naveen, Daver, Naval G., Ravandi, Farhad, Garcia-Manero, Guillermo, Borthakur, Gautam, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Kadia, Tapan M., Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven, Montalban-Bravo, Guillermo, Sasaki, Koji, Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Jabbour, Elias J., Masarova, Lucia, Thompson, Philip A., Wang, Sa, Konoplev, Sergej, Pierce, Sherry A., Ning, Jing, Qiao, Wei, Welch, John S., Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Publicado 2020

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

por Stahl, Maximilian, Abdel-Wahab, Omar, Wei, Andrew H., Savona, Michael R., Xu, Mina L., Xie, Zhuoer, Taylor, Justin, Starczynowski, Daniel, Sanz, Guillermo F., Sallman, David A., Santini, Valeria, Roboz, Gail J., Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nazha, Aziz, Nimer, Stephen D., Majeti, Ravindra, Little, Richard F., Gore, Steven, List, Alan F., Kutchroo, Vijay, Komrokji, Rami S., Kim, Tae Kon, Kim, Nina, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Greenberg, Peter L., Figueroa, Maria, Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Della Porta, Matteo G., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Brunner, Andrew M., Borate, Uma, Bennett, John M., Bejar, Rafael, Boultwood, Jacqueline, Loghavi, Sanam, Bewersdorf, Jan Philipp, Platzbecker, Uwe, Steensma, David P., Sekeres, Mikkael A., Buckstein, Rena J., Zeidan, Amer M.
Publicado 2023